{"preliminary_commentary":{"by_channel":{"youtube":3,"podcast":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab","relatlimab"]],"indication":null,"name":"RELATIVITY-1093","nct_id":"NCT06561386","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=relativity-1093-nct06561386. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RELATIVITY1093","arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-08-04","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":1000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Relatlimab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-07-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS) in randomized participants with PD-L1 1% to 49%","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2024-10-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","url":"https://clinicaltrials.gov/study/NCT06561386"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/relativity-1093-nct06561386"}